Does avatrombopag (Sucoxin) have to be used for a long time once it is taken?

Avatrombopag (Avatrombopag) is an oral thrombopoietin receptor agonist, mainly used to treat thrombocytopenia associated with chronic liver disease and chronic immune thrombocytopenia (ITP). Many patients will be concerned about whether "once they start using it, they must take it for a long time" when taking medicine. In fact, this issue needs to be judged based on the patient's underlying disease, changes in platelet levels, and clinical treatment goals. Not all patients require lifelong use.

First, for thrombocytopenia associated with chronic liver disease, avatrombopag is usually used as a short-term perioperative medication to increase platelet levels in a short period of time before patients undergo invasive surgery or treatment, thereby reducing the risk of bleeding. In this case, the patient does not need to take long-term medication and only needs to complete a course of treatment according to the doctor's instructions before surgery. Therefore, the use for this group of people is phased, not long-term maintenance treatment.

Second, avatropopag is used differently in patients with chronic immune thrombocytopenia (ITP). Some patients' platelet levels fluctuate greatly and tend to drop again after stopping the drug. At this time, doctors may recommend long-term maintenance medication to ensure stable platelet levels and avoid the risk of repeated bleeding. However, some patients, after a period of treatment, gradually improve their condition and maintain their platelet levels within a relatively safe range, and may gradually reduce the dose or even discontinue the drug. Therefore, not all ITP patients must take it for life.

Finally, the usage period of avatrombopag needs to be determined by a professional doctor based on the patient's specific situation. The key is to regularly monitor platelet levels, liver and kidney function, and the risk of bleeding or thrombosis, and dynamically adjust the course of treatment based on individualized treatment goals. Generally speaking, avatrombopag is not a drug that "once taken must be used for a long time." Instead, short-term or long-term use can be flexibly determined based on the patient's disease characteristics, treatment response, and risk assessment.

Reference materials:https://www.drugs.com/